Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy

Journal of Urology

Volumn 182, Issue 5, 2009, Pages 2257-2264

  Bhoopalam, Nirmala ^a   Campbell, Steven C ^a   Moritz, Thomas ^a   Broderick, William R ^a   Iyer, Padmini ^b   Arcenas, Anthony G ^c   Van Veldhuizen, Peter J ^d   Friedman, Nicholas ^a   Reda, Domenic ^a   Warren, Stuart ^e   Garewal, Harinder ^f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Kansas City Veterans Affairs   (United States)

^e University of New Mexico   (United States)

^f SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

androgen antagonists; osteoporosis; prostate; prostatic neoplasms; zoledronic acid

Indexed keywords

ANTIANDROGEN; CALCIUM; CREATININE; GONADORELIN AGONIST; PLACEBO; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; BODY MASS; BONE DENSITY; BONE NECROSIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HEALTH CARE SYSTEM; HOT FLUSH; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOTENSION; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SITTING; SMOKING; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; INTRAVENOUS DRUG ADMINISTRATION; PROSTATE TUMOR; VETERAN;

AGED; ANDROGEN ANTAGONISTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RISK FACTORS; VETERANS;

EID: 70350469958     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.07.046     Document Type: Article

References (24)

1. Ross R., and Small E. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 167 (2002) 1952
2. Eriksson S., Eriksson A., Stege R., et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calc Tiss Int 57 (1995) 97
3. Maillefert J., Sibilia J., Michael F., et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostate carcinoma. J Urol 161 (1999) 1219
4. Smith M.R., Lee W., Brandman J., et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23 (2005)
5. Shahinian V., Kuo Y., Freeman J., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154
6. Smith M.R., Boyce S., Moyneur E., et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175 (2006) 136
7. Daniel W., Dunn S., Ferguson D., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 (2000) 181
8. Campion J., and Maricic M. Osteoporosis in men. Am Fam Physician 67 (2003) 1521
9. Smith M.R., Fallon M.A., Lee H., et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 3841
10. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179 (2007) 152
11. Greenspan S.L., Nelson J.B., Trump D.L., et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 26 (2008) 4426
12. Smith M.R., Eastham J., Gleason D., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008
13. CGP 42446, Zometa® (Zoledronic Acid) Investigators' Brochure, 1998.
14. Green J., Muller K., and Jaeggi K.A. Preclinical pharmacology of CGP42′446, a new potent heterocyclic bisphosphonate compound. J Bone Min Res 9 (1994) 745
15. Michaelson M.D., Kaufman D.S., Lee H., et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing-hormone-agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25 (2007) 1038
16. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357 (2007) 1799
17. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of post-menopausal osteoporosis. N Engl J Med 356 (2007) 1809
18. Woo S., Hellenstein J., and Kalmar J. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753
19. Chang J., Green L., and Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 349 (2003)
20. Nelson K.M., Starkbaum G.A., and Reiber G.E. Veterans using and uninsured veterans not using Veterans Affairs (VA) health care. Public Health Rep 122 (2007) 93
21. Pandya MB, Bhoopalam N, Moritz T et al: A multicenter VA study of zoledronic acid in men on androgen deprivation therapy for prostate cancer with osteoporosis. Presented at Genitourinary Cancers Symposium, San Francisco, California, February 14-16, 2008, abstract 251.
22. Hollis B.W. Circulating 25-hydroxyvitamin D Levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135 (2005) 317
23. Ryan C., Huo D., Demers L., et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176 (2006) 972
24. Israeli R.S., Ryan C.W., and Jung L.L. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 179 (2008) 414